Literature DB >> 12500072

Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders.

John T Walkup1, Michael J Labellarte, Mark A Riddle, Daniel Pine, Laurence Greenhill, Rachel Klein, Mark Davies, Michael Sweeney, Caifeng Fu, Howard Abikoff, Sabine Hack, Brain Klee, James McCracken, Lindsey Bergman, John Piacentini, John March, Scott Compton, James Robinson, Thomas O'Hara, Sheryl Baker, Benedetto Vitiello, Louise Ritz, Margaret Roper.   

Abstract

OBJECTIVE: To examine whether age, gender, ethnicity, type of anxiety disorder, severity of illness, comorbidity, intellectual level, family income, or parental education may function as moderators and whether treatment adherence, medication dose, adverse events, or blinded rater's guess of treatment assignment may function as mediators of pharmacological treatment effect in children and adolescents with anxiety disorders.
METHOD: The database of a recently reported double-blind placebo-controlled trial of fluvoxamine in 128 youths was analyzed. With a mixed-model random-effects regression analysis of the Pediatric Anxiety Rating Scale total score, moderators and mediators were searched by testing for a three-way interaction (strata by treatment by time). A two-way interaction (strata by time) identified predictors of treatment outcome.
RESULTS: No significant moderators of efficacy were identified, except for lower baseline depression scores, based on parent's (but not child's) report, being associated with greater improvement (p < .001). Patients with social phobia (p < .05) and greater severity of illness (p < .001) were less likely to improve, independently of treatment assignment. Blinded rater's guess of treatment assignment acted as a possible mediator (p < .001), but improvement was attributed to fluvoxamine, regardless of actual treatment assignment. Treatment adherence tended to be associated (p = .05) with improvement.
CONCLUSIONS: In this exploratory study, patient demographics, illness characteristics, family income, and parental education did not function as moderators of treatment effect. Social phobia and severity of illness predicted less favorable outcome. Attribution analyses indicated that study blindness remained intact. The presence of concomitant depressive symptoms deserves attention in future treatment studies of anxious children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12500072     DOI: 10.1097/00004583-200301000-00006

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  16 in total

1.  fMRI predictors of treatment outcome in pediatric anxiety disorders.

Authors:  Erin B McClure; Abby Adler; Christopher S Monk; Jennifer Cameron; Samantha Smith; Eric E Nelson; Ellen Leibenluft; Monique Ernst; Daniel S Pine
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

2.  Monotherapy Insufficient in Severe Anxiety? Predictors and Moderators in the Child/Adolescent Anxiety Multimodal Study.

Authors:  Jerome H Taylor; Eli R Lebowitz; Ewgeni Jakubovski; Catherine G Coughlin; Wendy K Silverman; Michael H Bloch
Journal:  J Clin Child Adolesc Psychol       Date:  2017-09-28

3.  Can less be more? Open trial of a stepped care approach for child and adolescent anxiety disorders.

Authors:  Jeremy W Pettit; Yasmin Rey; Michele Bechor; Raquel Melendez; Daniella Vaclavik; Victor Buitron; Yair Bar-Haim; Daniel S Pine; Wendy K Silverman
Journal:  J Anxiety Disord       Date:  2017-08-29

4.  Mediators of change in the Child/Adolescent Anxiety Multimodal Treatment Study.

Authors:  Philip C Kendall; Colleen M Cummings; Marianne A Villabø; Martina K Narayanan; Kimberli Treadwell; Boris Birmaher; Scott Compton; John Piacentini; Joel Sherrill; John Walkup; Elizabeth Gosch; Courtney Keeton; Golda Ginsburg; Cindy Suveg; Anne Marie Albano
Journal:  J Consult Clin Psychol       Date:  2015-10-12

5.  Mediators of Treatment Outcomes for Anxious Children and Adolescents: The Role of Somatic Symptoms.

Authors:  Amy E Hale; Golda S Ginsburg; Grace Chan; Philip C Kendall; James T McCracken; Dara Sakolsky; Boris Birmaher; Scott N Compton; Anne Marie Albano; John T Walkup
Journal:  J Clin Child Adolesc Psychol       Date:  2017-02-26

Review 6.  Research in child and adolescent psychopharmacology: recent accomplishments and new challenges.

Authors:  Benedetto Vitiello
Journal:  Psychopharmacology (Berl)       Date:  2006-05-23       Impact factor: 4.530

Review 7.  Comorbidity of anxiety and depression in children and adolescents: 20 years after.

Authors:  Colleen M Cummings; Nicole E Caporino; Philip C Kendall
Journal:  Psychol Bull       Date:  2013-11-11       Impact factor: 17.737

Review 8.  Childhood anxiety disorders and developmental issues in anxiety.

Authors:  Paul Arnold; S Preeya Banerjee; Rashmi Bhandari; Elisa Lorch; Jennifer Ivey; Michelle Rose; David R Rosenberg
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

9.  Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.

Authors:  Madhukar H Trivedi; Patrick J McGrath; Maurizio Fava; Ramin V Parsey; Benji T Kurian; Mary L Phillips; Maria A Oquendo; Gerard Bruder; Diego Pizzagalli; Marisa Toups; Crystal Cooper; Phil Adams; Sarah Weyandt; David W Morris; Bruce D Grannemann; R Todd Ogden; Randy Buckner; Melvin McInnis; Helena C Kraemer; Eva Petkova; Thomas J Carmody; Myrna M Weissman
Journal:  J Psychiatr Res       Date:  2016-03-15       Impact factor: 4.791

10.  Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.

Authors:  Philip Hazell; Shuyu Zhang; Tomasz Wolańczyk; Joanne Barton; Mats Johnson; Alessandro Zuddas; Marina Danckaerts; Andrula Ladikos; David Benn; Roni Yoran-Hegesh; Pal Zeiner; David Michelson
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-03       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.